Resmed Inc (RMD) Stock Analysis
Verdict: HOLD
Best-in-class margins and market dominance are currently discounted by GLP-1 overhang and recent downgrades, creating a value trap risk.
Investment score: 62/100
Analysis as of
Is Resmed Inc stock worth reviewing? AI model thesis
ResMed is fundamentally robust but technically impaired. Its valuation is near historic lows, yet negative analyst sentiment and insider selling prevent a 'Buy' rating.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 90/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Resmed Inc opportunities and risks
What speaks for RMD
- Massive Valuation Gap vs. Peers
What speaks against RMD
- GLP-1 Disruption to Long-term Demand
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RMD | 18.8x | 5.1x | 12.6x | 61.7% | 27.4% | 6.2% |
| ISRG | 38.1x | 10.8x | 25.9x | 66.7% | 28.4% | 2.7% |
| BSX | 18.4x | 3.2x | 13.3x | 70.4% | 17.2% | 5.2% |
| EW | 47.5x | 7.3x | 29.8x | 78.0% | 15.4% | 2.3% |
| BDX | 39.6x | 2.7x | 15.6x | 46.5% | 5.3% | 5.5% |
| IDXX | 39.8x | 9.7x | 28.1x | 62.1% | 24.6% | 2.5% |
| Peer median | 39.6x | 7.3x | 25.9x | 66.7% | 17.2% | 2.7% |
Frequently asked questions about Resmed Inc (RMD)
Is RMD stock a good investment?
The cached TradeMates AI model rates Resmed Inc as HOLD with an investment score of 62/100. ResMed is fundamentally robust but technically impaired. Its valuation is near historic lows, yet negative analyst sentiment and insider selling prevent a 'Buy' rating. This is algorithmic model output, not personal investment advice.
Is RMD stock a buy?
The TradeMates model verdict for RMD is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.